Who are ALECSAT cell based immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): venom immunotherapy, TheraDerm, Novel dose adjustment of Alutard SQ, tree 12 SQ-Bet, Ibritumomab Tiuxetan (Zevalin), Cultured Thymus Tissue.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alecsat-cell-based-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ALECSAT cell based immunotherapy — Competitive Intelligence Brief

ALECSAT cell based immunotherapy (ALECSAT cell based immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy. Area: Oncology.

phase 1 Immunotherapy Oncology Biologic Live · refreshed every 30 min

Target snapshot

ALECSAT cell based immunotherapy (ALECSAT cell based immunotherapy) — CytoVac A/S. Cell-based immunotherapy targeting cancer cells

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ALECSAT cell based immunotherapy TARGET	ALECSAT cell based immunotherapy	CytoVac A/S	phase 1	Immunotherapy
venom immunotherapy	venom immunotherapy	Meir Medical Center	marketed	Immunotherapy; desensitization therapy
TheraDerm	TheraDerm	Massachusetts General Hospital	marketed	Topical immunotherapy
Novel dose adjustment of Alutard SQ	Novel dose adjustment of Alutard SQ	Beijing Tongren Hospital	marketed	Allergen immunotherapy
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
Ibritumomab Tiuxetan (Zevalin)	Ibritumomab Tiuxetan (Zevalin)	M.D. Anderson Cancer Center	marketed	Radioimmunotherapy agent; anti-CD20 monoclonal antibody	CD20
Cultured Thymus Tissue	Cultured Thymus Tissue	Sumitomo Pharma Switzerland GmbH	marketed	Thymic extract/cultured tissue immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
CytoVac A/S · 1 drug in this class
Hannover Medical School · 1 drug in this class
Pfizer · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
Zarour, Hassane, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALECSAT cell based immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/alecsat-cell-based-immunotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab